You can (very crudely) extrapolate the opportunity presented in the Triangle report for the global Zan + Anthracycline synergy market.
Global Anthracycline Market:
Triangle mBC/NBC CPACS pricing @ $15,000:
Discount rest of world pricing by 2/3 :
The market capture is unknown, but you can play around with the numbers (in USD).
This excludes the additional synergy opportunities identified by either RAC or our research partners with drugs that negatively impact HCM (Zan protects HCM).
And even this list excludes other cardiotoxic therapies identified by third parties; Radiotherapy, Immunotherapies etc.
Zan's TAM really isn't worth worrying about...
Cardioprotection thread, page-452
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.65 |
Change
0.170(11.5%) |
Mkt cap ! $279.8M | |||
| Open | High | Low | Value | Volume |
| $1.48 | $1.65 | $1.46 | $479.4K | 307.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 950 | $1.63 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.65 | 11353 | 4 |
View Market Depth
| Last trade - 16.10pm 03/06/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.63 |
Change
0.170 ( 10.6 %) |
||||
| Open | High | Low | Volume | ||
| $1.48 | $1.65 | $1.46 | 54704 | ||
| Last updated 15.57pm 03/06/2024 ? | |||||
| RAC (ASX) Chart |